While, IL-1β inhibition through small interfering RNA (siRNA) or neutralizing antibodies has previously demonstrated therapeutic efficacy in models of retinal degenerations, reducing immune cell recruitment to the outer retina and decreasing subsequent production of chemokines from Müller glia and RPE cells [4, 8], pro-active mitigation of inflammation by preventing the release of mature IL-1β and other pro-inflammatory cytokines by targeting GSDMD represents a novel approach to tackle inflammation. This evidence concerns the gene IL1B and retinal degeneration.